Anrukinzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Anrukinzumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target IL13
Clinical data
Legal status
?
Identifiers
CAS number 910649-32-0 N
ATC code None
UNII OU46IGC49F YesY
Chemical data
Formula C6452H9954N1714O2024S46 
Mol. mass 145.4 kDa
 N (what is this?)  (verify)

Anrukinzumab (IMA-638[1]) is a humanized monoclonal antibody designed for the treatment of asthma.[2]

Anrukinzumab was developed by Wyeth.

References[edit]

  1. ^ "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on June 12, 2008. Retrieved November 19, 2008. 
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council: Anrukinzumab, American Medical Association.